Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2019’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

- The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

- The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Celltrion Inc

Cidara Therapeutics Inc

ContraFect ...

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Celltrion Inc

Cidara Therapeutics Inc

ContraFect Corp

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

OPKO Health Inc

Sanofi

Sanofi Pasteur SA

Table of Contents

Table of Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections – Overview

Influenza A Virus, H3N2 Subtype Infections – Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections ...

Table of Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections – Overview

Influenza A Virus, H3N2 Subtype Infections – Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections – Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections – Companies Involved in Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections – Drug Profiles

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products

Influenza A Virus, H3N2 Subtype Infections – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2019

Number of Products under Development by Companies, H1 ...

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Alla Chem LLC, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AstraZeneca Plc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BlueWillow Biologics Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cidara Therapeutics Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by ContraFect Corp, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, H1 2019

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, H1 2019 (Contd..1), H1 2019

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2019

Number of Products under Development by Companies, H1 ...

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports